Dentsply Sirona Inc (XRAY)
Official siteHEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NASDAQ
Market Cap: $1.83B
Last updated: Nov 17, 2026 at 4:35 PM ET
Dentsply Sirona Inc (XRAY) Statistics
Dentsply Sirona (XRAY) has a market cap of $1.83B and an enterprise value of $3.83B. Its return on invested capital of 0.06% compares with a 7.04% median across 6 similar companies. Its trailing P/E of 6.4x is below its 10-year median of 18.7x.
Total Valuation
Enterprise value is 109.80% above the market cap, as debt exceeds cash.
| Market Cap | $1.83B |
|---|---|
| Enterprise Value | $3.83B |
| Latest price (Nov 17, 2026) | $8.60 |
Key Dates
The next earnings report is expected on Feb 24, 2027, covering the quarter ending Dec 31, 2026. The last ex-dividend date was Dec 26, 2025.
| Next Earnings Date | Feb 24, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 5, 2026 |
| Last Ex-Dividend Date | Dec 26, 2025 |
| Last Payment Date | Jan 9, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 0.5x and 1.3x. Its year-end P/E ranged from 7.2x to 29.3x from 2016 to 2025.
| P/E Ratio | 6.4x |
|---|---|
| Forward P/E | 6.1x |
| P/S Ratio | 0.5x |
| Forward P/S | 0.5x |
| P/B Ratio | 1.3x |
| P/FCF Ratio | 16.6x |
| P/OCF Ratio | 6.7x |
| PEG Ratio | 1.0 |
Enterprise Valuation
Counting debt and cash, the company is valued at 10.9x EBITDA and 36.1x free cash flow.
| EV / Sales | 1.1x |
|---|---|
| EV / EBITDA | 10.9x |
| EV / FCF | 36.1x |
Price Statistics
The stock is down 17.12% over 52 weeks and trades 7.92% below its 50-day average.
| Beta (1Y) | 1.14 |
|---|---|
| 52-Week Change | -17.12% |
| 1-Month Change | +2.14% |
| 3-Month Change | -22.03% |
| 6-Month Change | -11.70% |
| 5-Year Change | -83.34% |
| 10-Year Change | -83.45% |
| Total Return (1Y) | -15.57% |
| Total Return (3Y CAGR) | -32.43% |
| Total Return (5Y CAGR) | -29.39% |
| Return vs SPY (1Y) | -26.57% |
| Max Drawdown (1Y) | -42.64% |
| Max Drawdown (3Y) | -76.11% |
| Sharpe Ratio (1Y) | -0.34 |
| Correlation with SPY (1Y) | 0.33 |
| 50-Day Average | $9.34 |
| 200-Day Average | $11.15 |
| 52-Week Range | $8.14 to $14.76 |
| RSI (14 Days) | 38.7 |
| Average Volume (20 Days) | 5.22M |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 1.63x current liabilities, and total debt is 1.62x shareholder equity.
| Current Ratio | 1.63x |
|---|---|
| Quick Ratio | 1.04x |
| Debt / Equity | 1.62x |
| Debt / EBITDA | 6.45x |
| Debt / FCF | 21.36x |
| Interest Coverage | 0.02x |
Returns and Efficiency
Return on invested capital is 0.06% over the last 12 months, against a 5-year average of -8.38%.
| Return on Equity (ROE) | -9.00% |
|---|---|
| Return on Assets (ROA) | -2.35% |
| Return on Invested Capital (ROIC) | 0.06% |
| Return on Capital Employed (ROCE) | 0.05% |
| ROE (5Y Average) | -22.45% |
| ROA (5Y Average) | -7.32% |
| ROIC (5Y Average) | -8.38% |
| Asset Turnover | 0.66x |
| Inventory Turnover | 2.58x |
Scores
XRAY has an Altman Z-Score of 0.72, in the distress zone below 1.81, and a Piotroski F-Score of 6 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 0.72 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 6 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $3.58B over the last 12 months is down 1.35% from the 12 months before.
| Revenue | $3.58B |
|---|---|
| Revenue Growth (YoY) | -1.35% |
| Gross Profit | $1.81B |
| Operating Income | -$55.00M |
| Pretax Income | -$91.00M |
| Net Income | -$122.00M |
| EBITDA | $341.00M |
| EBIT | $2.00M |
| Reported EPS (TTM) | $1.35 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 26.01% of the $5.19B in total assets.
| Cash and Equivalents | $195.00M |
|---|---|
| Total Debt | $2.20B |
| Net Debt | $2.00B |
| Net Debt Per Share | $10.07 |
| Working Capital | $761.00M |
| Shareholder Equity | $1.35B |
| Book Value Per Share | $6.80 |
| Tangible Book Value | -$596.00M |
| Total Assets | $5.19B |
| Total Liabilities | $3.84B |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $169.00M of capital spending, operating cash flow left $103.00M of free cash flow.
| Operating Cash Flow | $272.00M |
|---|---|
| Capital Expenditures | $169.00M |
| Free Cash Flow | $103.00M |
| FCF Per Share | $0.52 |
| Depreciation and Amortization | $339.00M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -1.54%, against a 5-year average of -9.26%.
| Gross Margin | 50.52% |
|---|---|
| Operating Margin | -1.54% |
| Pretax Margin | -2.55% |
| Net Margin | -3.41% |
| EBITDA Margin | 9.54% |
| EBIT Margin | 0.06% |
| FCF Margin | 2.88% |
| Gross Margin (5Y Average) | 52.79% |
| Operating Margin (5Y Average) | -9.26% |
| Net Margin (5Y Average) | -11.62% |
Growth
Revenue fell 2.10% a year over 3 years, and EPS 8.57% a year.
| Revenue Growth (3Y CAGR) | -2.10% |
|---|---|
| Revenue Growth (5Y CAGR) | +1.96% |
| EPS Growth (3Y CAGR) | -8.57% |
| EPS Growth (5Y CAGR) | -2.34% |
| FCF Growth (3Y CAGR) | -34.38% |
| FCF Growth (5Y CAGR) | -28.64% |
| Book Value Per Share Growth (2Y CAGR) | -34.45% |
Dividends and Yields
XRAY pays out 11.72% of earnings as dividends.
| Dividend Per Share (Annual) | $0.64 |
|---|---|
| Dividend Yield | 7.44% |
| Dividend Growth (3Y CAGR) | +8.58% |
| Dividend Growth (5Y CAGR) | +9.86% |
| Payout Ratio | 11.72% |
| Earnings Yield | 15.63% |
| FCF Yield | 6.01% |
| Buyback Yield | 0.76% |
Stock Splits
The last split was a 2-for-1 forward split on Jul 18, 2006.
| Last Split Date | Jul 18, 2006 |
|---|---|
| Split Type | Forward split |
| Split Ratio | 2:1 |
Peer Position
Against 9 similar companies, XRAY has the lowest P/E.
P/E RatioPeer median 27.7x
P/S RatioPeer median 3.4x
ROICPeer median 7.04%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +9.06%
Dividend YieldPeer median 0.00%
| P/E Ratio | 6.4x vs 27.7x median |
|---|---|
| P/S Ratio | 0.5x vs 3.4x median |
| ROIC | 0.06% vs 7.04% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | -1.35% vs +9.06% median |
| Dividend Yield | 7.44% vs 0.00% median |
Analyst Forecast
Consensus estimates put revenue growth at -2.25% and EPS growth at -11.76% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | -2.25% |
|---|---|
| EPS Growth Forecast (2Y CAGR) | -11.76% |
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About XRAY
What is XRAY's market cap?
Dentsply Sirona has a market cap of $1.83B. Its enterprise value, which adds debt and subtracts cash, is $3.83B.
What is XRAY's P/E ratio?
Dentsply Sirona has a trailing P/E ratio of 6.4x and a forward P/E of 6.1x.
How many shares of XRAY are outstanding?
Dentsply Sirona has 199.20M shares outstanding. The count is down 0.15% from a year earlier.
Does XRAY pay a dividend?
Yes. Dentsply Sirona pays $0.64 a share a year, a dividend yield of 7.44%.
How much debt does XRAY have?
Dentsply Sirona has $2.20B of total debt and $195.00M of cash and equivalents, a net debt position of $2.00B.
XRAY pages: Overview, Dividends, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors, Government Contracts